NasdaqGM:RYTMBiotechs
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates
Why Rhythm Pharmaceuticals is back in focus after fresh trial data
Rhythm Pharmaceuticals (RYTM) is back on investors’ radar after new positive Phase 3 TRANSCEND data for setmelanotide in acquired hypothalamic obesity, alongside advancing US and Japan regulatory filings and fresh financing moves.
See our latest analysis for Rhythm Pharmaceuticals.
At a share price of $93.52, Rhythm’s 1-day share price return of 2.25% and recent product and financing announcements sit against a softer 30-day...